LRI Board Member Leads Clinical Trial Researching Potential Lupus Treatment

LRI Board member Dr. Daniel Wallace will be leading a clinical trial of a potential treatment for lupus.  The drug, milatuzumab, is being developed by the biopharmaceutical company Immunomedics, Inc. Conducted at Cedars Sinai Medical Center in Los Angeles, the trial will recruit approximately 30 lupus patients.

For mor information click here http://www.immunomedics.com/pdfs/news/2013/pr09302013a.pdf